Global Acute Coronary Syndrome (ACS) Market 2015-2019

Global Acute Coronary Syndrome (ACS) Market 2015-2019

About ACS

ACS is a condition that results in sudden and reduced blood flow to the heart. ACS is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and short-term mortality. On the basis of evidence of heart muscle damage and changes in the ST-tracing of the ECG, ACS is classified into three categories: STEMI, NSTEMI, and UA. ACS is treatable if it is diagnosed quickly. The treatment options for ACS vary, depending on the signs, symptoms, and overall health condition.

TechNavio's analysts forecast the Global ACS market to grow at a CAGR of 13.24 percent over the period 2014-2019.

Covered in this Report

The Global ACS market can be divided into three segments: STEMI, NSTEMI, and UA. This report covers the present scenario and the growth prospects of the Global ACS market for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ACS.

TechNavio's report, the Global ACS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ACS market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions

  • Americas
  • EMEA
  • APAC
Key Vendors
  • Astra Zeneca
  • BMS
  • Eli Lilly
  • GSK
  • Sanofi
Other Prominent Vendors
  • AbbVie
  • Amgen
  • Bayer
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Portola Pharmaceuticals
  • Teva Pharmaceutical
  • Market Driver
  • Increase in Aging Population
  • For a full, detailed list, view our report
  • Market Challenge
  • Multiple Patent Expirations
  • For a full, detailed list, view our report
  • Market Trend
  • Increase in Awareness
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

TechNavio Announces the Publication of its Research Report – Global ACS Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global ACS Market: AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc and Sanofi SA

Other Prominent Vendors in the market are: AbbVie, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Merck, Novartis, Pfizer, Portola Pharmaceuticals and Teva Pharmaceutical.

Commenting on the report, an analyst from TechNavio’s team said: “Growing public awareness of ACS is one of the key trends being witnessed in this market. Several organizations are initiating various programs to spread awareness about ACS for the early diagnosis and treatment of the syndrome and to decrease mortality and morbidity from heart attacks.”

According to the report, the elderly population, from middle-aged and older, are more prone to developing ACS because with aging, plaque accumulates in the arteries, resulting in the narrowing of the arterial passage and difficulty in blood flow to the heart.

Further, the report states that patent expiry of a drug results in the loss of the exclusive market for that particular drug, thus leading to a rapid decline in its sales. Patent expiry of a drug results in the loss of the exclusive market, resulting in a rapid decline in the sales of that particular drug.

Companies Mentioned

Astra Zeneca , BMS, Eli Lilly, GSK, Sanofi, AbbVie, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo , Johnson & Johnson, Merck, Novartis, Pfizer, Portola Pharmaceuticals, Teva Pharmaceutical

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
    • Table Spectrum of ACS
  • Disease Overview
    • Understanding the Disease
      • Table Overview of ACS
    • Burden of Disease
    • Etiology
    • Pathophysiology
      • Myocardial Dysfunction
      • MI
      • Electrical Dysfunction
        • Table Pathogenesis of ACS
    • Prognosis
    • Epidemiology
      • Table Hospitalized Incident Cases of ACS 2014-2019 (millions)
      • Prevalence of Coronary Artery Disease
        • Table Epidemiologic Transition of CV Diseases
    • Diagnosis
      • ECG
      • Blood Tests
      • Nuclear Scan
      • CT
    • Management
      • Table Initial Drug Therapy for ACS
      • Table Adjunctive Drug Therapy for ACS
      • Table Surgery and Other Procedures
  • ACS Pipeline Landscape
    • Key Pipeline Molecules
  • Market Landscape
    • Market Overview
      • Table Snapshot of Global ACS Market 2014
    • Market Size and Forecast
      • Table Global ACS Market 2014-2019 (US$ billion)
      • Table Global ACS Market Share of Branded and Generic Drugs 2014 and 2019 (in Percent)
    • Five Forces Analysis
  • Market Segmentation by ECG Output
    • Table Segmentation of Global ACS Market by ECG Output
    • Table Diagrammatic Representation of STEMI, NSTEMI, and UA
    • Table Segmentation of Global ACS Market by ECG Output 2014
  • Geographical Segmentation
    • Table Global ACS Market by Geography 2014
  • Buying Criteria
  • Market Growth Drivers
    • Table Drivers of Global ACS Market
    • Table Comparison of Elderly Population 2012 and 2050 (Aged 65 and Older)
  • Drivers and their Impact
  • Market Challenges
    • Table Challenges in Global ACS Market
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Trends in Global ACS Market
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • AstraZeneca
        • Table Global Revenue of AstraZeneca for CV and Metabolic Diseases 2011-2013 (US$ million)
        • Table Estimated Filings of Brilinta/Brilique
        • Table Line Extensions for Brilinta/Brilique
        • Table Global Revenue of Brilinta/Brilique by AstraZeneca 2011-2013 (US$ million)
      • Bristol-Myers Squibb
        • Table Global Revenue of Plavix by Bristol-Myers Squibb 2010-2012 (US$ million)
      • Eli Lilly
        • Table Revenue of Eli Lilly by Therapeutic Area 2013
        • Table Global Revenue of Effient by Eli Lilly 2010-2013 (US$ million)
      • GlaxoSmithKline
        • Table Global Revenue of Arixtra by GlaxoSmithKline 2011-2013 (US$ million)
      • Sanofi
        • Table Global Revenue of Plavix by Sanofi 2011-2013 (US$ million)
        • Table Global Revenue of Lovenox by Sanofi 2011-2013 (US$ million)
    • Other Prominent Vendors
  • Key Vendor Analysis
    • AstraZeneca
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table AstraZeneca plc: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2011-2013
        • Table AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
      • Revenue by Geography
        • Table AstraZeneca: Revenue by Geography 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Bristol-Myers Squibb
      • Key Facts
      • Business Overview
      • Key Product Offerings
        • Table Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
      • Revenue by Geography
        • Table Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Eli Lilly
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue
        • Table Eli Lilly: Business Segmentation by Revenue 2013
        • Table Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
      • Revenue by Geography
        • Table Eli Lilly: Revenue by Geography 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • GlaxoSmithKline
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table GlaxoSmithKline: Business Segmentation 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Revenue by Geography
        • Table GlaxoSmithKline: Revenue by Geography 2013
      • Pipeline Products
        • Table GlaxoSmithKline: Pipeline Products 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Sanofi
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Sanofi: Business Segmentation
      • Revenue by Business Segmentation
        • Table Sanofi: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Sanofi: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Revenue by Geography
        • Table Sanofi: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook